



CompuMed Engages Liolios Group to Lead New Investor Relations Program

LOS ANGELES, Feb 09, 2010 -- CompuMed, Inc. (<http://www.compumed.net>), a medical informatics and software company, has engaged Liolios Group, Inc. to help lead the company's new investor relations and financial communications program.

"We feel the time has arrived given the progression of our business to hire a team of experienced professionals like Liolios Group to help us deliver our message to our shareholders and build our profile in the investment community," said Maurizio Vecchione, president and CEO of CompuMed. "Liolios Group not only understands the medical information and e-health industry, but they also bring a proven track record of assisting growth companies in building quality, long-term relationships with the investment community."

Liolios Group will collaborate with CompuMed management to refine the company's message and outline a new communications strategy, including identifying key performance metrics which investors should focus upon as they track the company's progress. Over the coming months, Liolios Group will also schedule investor meetings and financial conferences, targeting investors and key influencers such as analysts, fund managers, and investment advisors.

To receive a corporate profile on CompuMed or to learn more about the company's progress, please contact Liolios Group at 949-574-3860 or email info@liolios.com.

About Liolios Group, Inc.:

Liolios Group is a highly selective and comprehensive investor relations firm specializing in small and micro-cap companies. The company aims to deliver superior performance in corporate messaging and positioning, investor awareness, analyst and financial press coverage, and capital attraction. Founded in 1996 in Newport Beach, California, Liolios Group partners each have more than 15 years experience in finance and investments,

and have represented more than 120 companies in a wide range of industries. For more information about Liolios Group, go to www.liolios.com.

About CompuMed:

CompuMed, Inc. (OTCBB:CMPD) develops and markets products and services that combine telemedicine, medical informatics and advanced imaging. The CardioGram is one of the first telecommunication networks designed to remotely interpret electrocardiograms and is used by private practice, government and corporate healthcare providers nationwide. The OsteoGram is a noninvasive diagnostic system that provides effective and accurate bone density measurement for screening for osteoporosis and assessing hip fracture risk. The OsteoGram has significant cost advantages over other technologies in the marketplace. The OsteoGram and CardioGram are cleared by the FDA and reimbursable by Medicare. CompuMed distributes its products worldwide both directly and through OEM partners. Visit CompuMed online at www.compumed.net and twitter:@compumed.

Statements contained in this press release that are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue and earnings growth, results of contracts and other financial results, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including statements concerning the Company's plans, objectives, expectations and intentions are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements are subject to uncertainties and risks including, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, product and service demand and acceptance, changes in technology, ability to raise capital, the availability of appropriate acquisition candidates and/or business partnerships, economic conditions, the impact of competition and pricing, capacity and supply constraints or difficulties, government regulation and other risks identified in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-KSB and Quarterly Reports on Form 10-QSB. All such forward-looking statements are expressly qualified by these cautionary statements. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect events, conditions or circumstances on which any such statement is based after the date hereof, except as required by law.

Company Contacts:

Susan Tellem, APR - Tellem Worldwide, +1 310-313-3444
stellem@tellem.com

or

Investor Relations Contacts:

Liolios Group, Inc. Ron Both or Cody Slach - +1 949-574-3860
info@liolios.com